Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Sep 18, 2024 8:57am
68 Views
Post# 36228659

RE:RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.

RE:RE:RE:RE:RE:RE:Quentin30 is a pathological prevaricator.as the CEO of ONCY, anything he said wasn't authorised by ONCY..?

that's interesting... Kirk Look, the CFO of ONCY is talking to us about science... hmmm, is what he's telling us authorised by ONCY.

When Matt told us AWARE-1 would be complete in a few months, did he have ONCY's authorisation..??

atta boy... your logic is really helping would be investors... 

it reads something like... Any predictions that management make on the future of Pela cannot be taken at face value.

ALL trials are late, all results are confounding, CMOs disappear on a 2-3 year timeline, business development officers vanish without word, promised trials that would half the cost of a Phase III suddenly get canned, business partners who are listed by way of validating ONCY's product no longer mention Pela on their own pipeline slides , and the list of red fl;ags goes on and on...

Yet you claim, AA is around the corner... LOL... NO, it isn't... remember, ONCY already has the data... the Bracelet-1 trial ended in July...  It doesn't take 3 months to work out if you have a definitive signal...!!!

Noteable, you still can't tell us when the inflection point is can you..? because you know that any such moment will be precded by a reverse split... , 5 for 1 this time?
<< Previous
Bullboard Posts
Next >>